Ask about this productRelated genes to: PTGDS antibody
- Gene:
- PTGDS NIH gene
- Name:
- prostaglandin D2 synthase
- Previous symbol:
- -
- Synonyms:
- PGDS, L-PGDS
- Chromosome:
- 9q34.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-07-13
- Date modifiied:
- 2016-10-05
Related products to: PTGDS antibody
Related articles to: PTGDS antibody
- Trabecular meshwork (TM) fibrosis, which causes ocular hypertension (OHT), remains a key therapeutic challenge in glaucoma. Given the emerging link between circadian rhythm disruption and glaucoma, we sought to identify novel fibrotic mediators related to circadian genes, and screen for potential inhibitors to assess their therapeutic effect. - Source: PubMed
Yuan HongzhiChe YutongZhang YuqingCai ZiyiPing Yu-TzuWang XiaoranYang Yangfan - Environmental pollutant exposure has been associated with chronic kidney disease (CKD), yet specific chemicals related to renal function variation remain incompletely characterized. - Source: PubMed
Publication date: 2026/04/13
Zhou XiaoshanDeng WeitianChu ChengshuangWu QingqingCao YuqingChen WanjiaLiu WangyiYue LingXiao ShifuLi QingrunYin YuanyuanGao XiaojingZeng RongDeng Yueyi - Neuroblastoma is a pediatric malignancy characterized by significant clinical heterogeneity. Although MYCN amplification is a well-established marker of high-risk disease, its interplay with the tumor immune microenvironment-particularly tumor-associated macrophages (TAMs)-remains poorly understood. In this study, we developed an integrated gene signature incorporating genes associated with both MYCN amplification status and TAM infiltration, leading to the identification of 16 differentially expressed genes implicated in both biological processes. Six of these genes (CMBL, LY6E, KLRB1, CTSH, CD3D, and PTGDS) were utilized to construct a risk-scoring model that effectively stratified neuroblastoma patients into high- and low-risk groups with significantly distinct clinical outcomes ( < 0.001). Notably, LY6E emerged as the most prognostically significant gene within the signature. More importantly, we revealed that LY6E modulates M2-type macrophage polarization in neuroblastoma for the first time, suggesting a novel mechanism through which it may contribute to shaping an immunosuppressive tumor microenvironment. - Source: PubMed
Publication date: 2026/04/15
Li LijuanZeng YuZhang QinfenZhuang GaojianLiu YuWang XuanWang Yuqi - - Source: PubMed
Publication date: 2026/04/09
Wang WeiweiNiu ChichengZhao CanbinXu QingyuanGuo LiangLiu JinfuZeng Ping - Glaucoma, a leading cause of irreversible blindness, involves oxidative stress-mediated damage to retinal photoreceptors. This study elucidates the molecular mechanism by which curcumin, a natural compound, protects retinal cells in glaucoma. Molecular docking and biochemical assays revealed that curcumin binds prostaglandin D2 synthase (PTGDS) with high affinity, leading to marked upregulation of PTGDS expression. In vitro experiments using HO-treated 661 W retinal cells showed that PTGDS overexpression suppressed reactive oxygen species (ROS) accumulation, inflammation, and apoptosis while enhancing proliferation. Transcriptomic profiling showed that PTGDS knockdown disrupted nuclear factor erythroid 2-related factor 2 (NRF2) signaling and downregulated key antioxidant genes. Mechanistically, curcumin-induced PTGDS expression activated NRF2, increased phosphorylation of AMP-activated protein kinase (AMPK) and ERK, upregulated Bcl-2, and inhibited Bax and caspase-3 cleavage. These effects were abolished by PTGDS knockdown. In vivo validation using a paraquat-induced glaucoma mouse model confirmed that curcumin improved visual function (via pattern electroretinography, optokinetic response, and visual evoked potentials), reduced retinal oxidative stress markers (malondialdehyde, superoxide dismutase, glutathione), and attenuated inflammatory cytokines (Interleukin [IL]-1β, Tumor Necrosis Factor Alpha [TNF-α]). PTGDS knockdown negated these therapeutic benefits. Together, these findings establish PTGDS as a critical mediator of curcumin-induced NRF2 activation, highlighting a novel cross-species neuroprotective pathway and a promising therapeutic target for glaucoma. - Source: PubMed
Publication date: 2026/04/01
Wang YingMa YuZhang ShuoNie Lili